India’s locally developed Covid vaccine, Covaxin, may soon receive the World Health Organization’s emergency use list, possibly allowing its recipients to travel abroad without mandatory quarantine, said Wednesday NITI member Aayog, Health, VK Paul.
Data sharing and evaluation is ongoing and a positive decision could soon be made, he said.
“Data sharing and evaluation has been the subject of several reviews and we are near a decision point.
“We must give the WHO time to make their decisions based on science. However, we hope that these decisions can be made quickly as people who receive Covaxin have certain travel requirements. Most of us who have chosen concomitantly are important in terms of licensing. We hope for a quick decision, ”said Dr Paul.
“We believe that a positive decision could be taken before the end of the month,” he added.
In August, Indian Minister of Health Mansukh Mandaviya also met with WHO Chief Scientist Dr Soumya Swaminathan and had discussions on WHO approval of Covaxin.
Vaccine developer Bharat Biotech submitted data from Phase 3 clinical trials that demonstrated 77.8% efficacy to the Subject Matter Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) .
WHO has so far approved Covid-19 vaccines by Pfizer-BioNTech, AstraZeneca, Johnson and Johnson, Moderna and Sinopharm.